Psoriasis and metabolic syndrome

Area of Science:

• Immunodermatology
• Cardiology
• Endocrinology

Background:

• Psoriasis is a chronic inflammatory disease linked to metabolic syndrome comorbidities like obesity and hypertension.
• Metabolic syndrome's development may involve adipocytokines, including tumor necrosis factor-α (TNF-α) and adiponectin.
• Psoriasis patients exhibit a higher prevalence of metabolic syndrome compared to those with other skin conditions.

Purpose of the Study:

• To review the association between psoriasis and metabolic syndrome, focusing on adipocytokines.
• To evaluate the efficacy of biologic agents in managing psoriasis in patients with metabolic syndrome.

Main Methods:

• Literature review of studies on psoriasis, metabolic syndrome, and adipocytokines.
• Analysis of the role of anti-TNF-α agents in treating psoriasis and associated metabolic syndrome.

Main Results:

• Psoriasis shares common pathogenic pathways with metabolic syndrome, particularly involving adipocytokines like TNF-α.
• Biologic agents, specifically anti-TNF-α antibodies, are effective first-line treatments for psoriatic patients with metabolic syndrome.

Conclusions:

• Psoriasis and metabolic syndrome are interconnected through inflammatory pathways and adipocytokine dysregulation.
• Biologic therapies targeting TNF-α offer a dual benefit for patients with psoriasis and metabolic syndrome.